Rexford Newbould1, Courtney Bishop1, Antonio Martin-Bastida2, and David Dexter2
A double-blind placebo-controlled clinical trial of an iron
chelation therapy was performed in 25 subjects with Parkinson’s disease (PD)
and 12 healthy matched controls. Two MRI
measures of brain iron at each of three visits at baseline, 3 months, and 6
months were derived from a high resolution 3D multiecho volume: T2* and QSM
maps. T2* values significantly lengthened in six of nine pre-defined ROIs by
the final visit in the highest dose group.
QSM values , however, did not change with treatment. This differential trajectory between relaxation
and susceptibility may result from ferritin’s complex relaxation behavior.
